4 C
Beijing
Wednesday, March 4, 2026

RadNet Bolsters AI Radiology Arm with $270 Million Acquisition of Gleamer

RadNet acquires French radiology AI firm Gleamer for up to $270 million, expanding its DeepHealth subsidiary's capabilities and aiming for global leadership in AI-powered radiology solutions.

Turkey’s Borsa İstanbul Navigates Short Selling Bans and Lifts Amidst Economic Shifts

Explore the series of short selling bans and subsequent lifts on Turkey's Borsa İstanbul, driven by economic, political, and geopolitical factors, and their impact on market stability and investor confidence.

OneSpan Bolsters Mobile Security with Acquisition of Build38

OneSpan Inc. has completed the acquisition of Build38, enhancing its mobile security offerings with advanced app shielding, RASP technology, and AI-driven threat intelligence.

Chinese Scientists Develop Rapid-Detection Mechanism for High Blood Pressure Gene Variants

ChinaChinese Scientists Develop Rapid-Detection Mechanism for High Blood Pressure Gene Variants

Chinese scientists have developed a new rapid-detection mechanism that could pave the way for more personalized treatment for high blood pressure patients. Millions of people worldwide still fail to achieve effective blood pressure control, although there are drugs that can control hypertension, a key risk factor for heart diseases. However, the new mechanism, developed by researchers from the Institute of Chemistry under the Chinese Academy of Sciences, could change that.

The researchers modified a commonly-used fluorescent detection technique to detect 10 gene variants called single nucleotide polymorphisms (SNPs) associated with hypertension. The test used a simple design through which two SNPs can be detected with one reaction. The mechanism was applied retrospectively to 150 blood samples from hospitalized patients with hypertension in China, and it successfully detected several disease-linked SNPs.

In a week-long clinical trial involving 100 patients with hypertension, the researchers applied the technique and used the test results to personalize medication choices for 50 percent of the participants based on drug class-associated risks. Compared with those who received standard hypertension therapy, the precision medicine group achieved better blood pressure control in less time, decreasing from 5.82 days to 4.06 days.

The researchers believe that this system could be applied to maximize the efficacy of hypertension medication and reduce rates of uncontrolled hypertension. This scientific breakthrough can pave the way for more personalized treatment in the future, offering hope to millions of patients who struggle with high blood pressure.

Read More:

Check out our other content

Check out other tags:

Most Popular Articles